Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2187 - Real-world survival results of metastatic melanoma patients treated with ipilimumab in the Netherlands


09 Oct 2016


Poster display


Anouk Jochems


Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379


A. Jochems1, M. Schouwenburg1, M. Aarts2, F. van den Berkmortel3, A. van den Eertwegh4, G. Groenewegen5, J. de Groot6, J.B.A.G. Haanen7, G. Hospers8, E. Kapiteijn9, R. Koornstra10, W. Kruit11, B. Leeneman12, M. Louwman13, D. Piersma14, R. van Rijn15, A.J. Ten Tije16, G. Vreugdenhil17, M. Wouters18, J. van der Hoeven9

Author affiliations

  • 1 Medical Oncology, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 2 Medical Oncology, Maastricht University Medical Center (MUMC), Maastricht/NL
  • 3 Medical Oncology, Zuyderland MC, Heerlen/NL
  • 4 Medical Oncology, Vrije University Medical Centre (VUMC), Amsterdam/NL
  • 5 Medical Oncology, University Medical Center Utrecht, Utrecht/NL
  • 6 Medical Oncology, Isala Klinieken, Zwolle/NL
  • 7 Department Of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 8 Medical Oncology, University Hospital Groningen (UMCG), Groningen/NL
  • 9 Medical Oncology, Leiden University Medical Center (LUMC), Leiden/NL
  • 10 Medical Oncology, Radboud University Medical Centre Nijmegen, Nijmegen/NL
  • 11 Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam/NL
  • 12 X, Institute for Medical Technology Assessment, Rotterdam/NL
  • 13 Epidemiology, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht/NL
  • 14 Medical Oncology, Medisch Spectrum Twente (MST), Enschede/NL
  • 15 Medical Oncology, Medical Center Leeuwarden, Leeuwarden/NL
  • 16 Medical Oncology, Amphia ziekenhuis, Breda/NL
  • 17 Medical Oncology, Maxima Medical Center, Eindhoven/NL
  • 18 Department Of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/NL


Abstract 2187


Since 2012 ipilimumab is available for metastatic melanoma patients in the Netherlands. We investigated the survival of this treatment in real-world clinical practice.


Data were retrieved from the Dutch Melanoma Treatment Registry (DMTR), follow up data cut-off April 14th 2016. This registry records detailed data on tumor and patient characteristics, systemic treatment, grade 3 and 4 adverse events (according to the CTCAE v. 4), outcome and resource use of all patients with unresectable stage IIIc and stage IV melanoma. Kaplan-Meier estimates are used to assess the median overall survival (OS) and survival rates.


From July 2012 until April 2016, 891 patients received at least one cycle of ipilimumab. 458 patients (51%) had received a previous therapeutic regimen. A shift towards applying ipilimumab in treatment naïve patients with metastatic melanoma was seen from February 2014 as at that time approval by the National Health Care Institute was obtained for this patient group. Median follow-up was 21 months (95% CI 18.6-23.3) for previously treated patients and 11.3 months (95% CI 10.4-12.3) for treatment naïve patients. The median overall survival for previously treated patients was 8.0 months (95% CI 6.8-9.3) with a one year survival rate of 37% (95% CI 32-42) and a two year survival rate of 24% (95% CI 19-28). In this group, patients presenting with normal LDH (71%) had a median OS of 9.9 months (95% CI 8.4-11.5). For treatment naïve patients the median overall survival was 14.5 months (95% CI 11.8-17.3) and the one-year survival rate was 54% (95% CI 48-60). Two-year survival rate could not be calculated because the follow-up duration was too short.


The discrepancy between real-world one year survival rates of previously treated patients receiving ipilimumab and pivotal trial results could be due to more stringent patient selection in clinical trials. Inexperience with disease management outside of a controlled clinical trial may have contributed as well. Importantly, two year survival rates for previously treated patients and one year survival rate of treatment naïve patients are consistent with patient outcome found in clinical trials with ipilimumab.

Clinical trial identification

Data is retrieved from a registry. Trial protocol number is not applicable.

Legal entity responsible for the study

Dutch Society for Medical Oncology (NVMO)


1. The Netherlands Organisation for Health Research and Development (ZonMw); 2. Roche; 3. Bristol- Myers Squibb (BMS); 4. MSD; 5. Novartis Oncology.


A. van den Eertwegh: Advisory/consulting role: BMS, Roche, MSD, Novartis, GSK Research funding: Roche. G. Groenewegen: Speakers bureau Astellas. J-W. de Groot: Consulting/ advisory role: Servier, Amgen, BMS, Bayer, Celgene, Merck, Roche. J.B.A.G. Haanen: Consulting/Advisory role: BMS, MSD, Roche, Novartis, Pfizer, Neon Research funding: BMS, GSK, MSD. R. Koornstra: Consulting/Advisory role: BMS, MSD, Roche, Novartis Honoraria: MSD. W. Kruit: Consulting/Advisory role: BMS, Novartis, GSK. D. Piersma: Consulting/Advisory role: Amgen, Novartis Research Funding: Novartis, Astra Zeneca, BMS. R. van Rijn: Consulting/Advisory Role: BMS, Amgen, Takeda Research funding: Celgene, GSK. G. Vreugdenhil: Consulting/Advisory role: BMS. M. Wouters: Research funding: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings